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Abstract: We present an interesting case of pemphigus vulgaris with severe and rare eye 
manifestations. An old lady with systemic and ocular manifestations of pemphigus vulgaris was 
treated with systemic corticosteroids and immunosuppressants, with no effect. Subconjunctival 
injection of triamcinolone acetate reduced the ocular signs and led to gradual reduction of the 
systemic medications.
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Introduction
Pemphigus vulgaris (PV) is an uncommon (0.5–3.2 cases per 100,000), potentially 
life-threatening (5%–15%), autoimmune bullous mucocutaneous disease,1 which can 
rarely affect the eyes. Autoantibodies are formed against desmoglein, the “glue” that 
attaches adjacent epidermal cells. When autoantibodies attack desmogleins, the cells 
become separated from each other, a phenomenon called acantholysis. This causes 
blisters and erosions.2,3
We present a case of a patient with ocular manifestations of PV resistant to systemic 
and topical medication, which was successfully treated with subconjunctival injections 
of triamcinolone acetonide (TA).
Case report
A 76-year-old woman, suffering from PV, was referred to our department due to 
acute onset of intense burning and foreign body sensation in her right eye, despite her 
treatment with systemic methylprednisolone 15 mg/day and azathioprine 100 mg/day 
due to PV . PV was diagnosed clinically and by performing (a) histopathology from the 
edge of a blister, (b) direct immunofluorescence (DIF) on normal-appearing perilesional 
skin, and (c) indirect immunofluorescence (IDIF). Acantholytic cells were found in 
a Tzanck smear, taken from the base of an erosion, which helped to differentiate PV 
from pemphigus foliaceous.
Her best corrected visual acuity was 6/9 bilaterally. Slitlamp examination revealed 
pronounced conjunctival hyperaemia, mucus secretions, ulcerative erosions involving 
the palpebral conjunctiva at the right lower eyelid margin (Figure 1) and punctate 
corneal epithelial erosions involving the inferior part of the cornea of the same eye. 
Schirmer’s test without anesthetic was markedly reduced (3 mm) as well as the tear 
break up time (BUT) (3 seconds).
The disease was considered uncontrolled due to the appearance of new symptoms 
and signs. Therefore the dose of methylprednisolone was increased to 40 mg/day, Clinical Ophthalmology 2010:4 366
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year after the second injection the patient is still asymptom-
atic without signs of recurrence.
Discussion
Ocular pemphigus is probably underdiagnosed and its 
frequency appears underestimated.3 PV is recognized by a 
dermatologist from the appearance and distribution of the 
skin lesions. Definitive diagnosis requires examination of 
a skin biopsy from the edge of a blister by a pathologist. 
The pathologist looks for an intraepidermal vesicle caused 
by acantholysis. Definitive diagnosis also requires the 
demonstration of anti-desmoglein autoantibodies by direct 
immunofluorescence on the skin biopsy. These antibodies 
appear as IgG deposits along the desmosomes between 
epidermal cells, a pattern reminiscent of chicken wire. 
Anti-desmoglein antibodies can also be detected in a blood 
sample using the ELISA technique. A high titer of cANCA 
is claimed to be an important feature of the disease.3,4
and the azathioprine was replaced by cyclophosphamide 
100 mg daily. In addition, the patient was treated with topi-
cal dexamethasone 0.1% daily and frequent instillation of 
unpreserved carbomer 0.3%. This therapeutic regime was 
applied for 2 months without symptomatic improvement. 
Hence, a subconjunctival injection of TA 20 mg in 0.5 mL 
(Kenacort® 40 mg/mL; Bristol-Myers Squibb) was given 
after informed consent was obtained, but without stopping 
the systemic treatment. There were no adverse effects of TA 
noted at any time. Two weeks following the TA injection 
the patient’s symptoms were reduced significantly – the eye 
was less inflamed and the conjunctival ulcers were reduced 
in size. Due to the initial positive response to the TA injec-
tion a second injection was given at that time. Three months 
later the symptoms had improved significantly and the ulcers 
had disappeared (Figure 2), enabling us to taper further the 
systemic treatment. The Schirmer’s test was also increased to 
6 mm as well as the BUT was prolonged to 6 seconds. One 
Figure 1 The right eye of the patient with pemphigus vulgaris: Ulcerative erosions can be seen at the palpebral conjunctiva at the lower eyelid margin.Clinical Ophthalmology 2010:4 367
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Figure 2 The lid margin 3 months after the second subconjunctival injection of triamcinolone acetonide. No erosions are seen at the palpebral conjunctiva of the right lower 
eyelid margin.
Ocular involvement with PV is very rare.2 The most 
  characteristic findings are conjunctival hyperemia, 
  conjunctivitis, eye irritation and mucus secretions.5 Catarrhal 
conjunctivitis is very common in PV, while bullae and 
  conjunctival erosions are seen rarely.5,6 Conjunctival fibrosis 
is very rare2 as is corneal involvement.7
The therapeutic approach for the treatment of PV requires 
a systemic therapy with steroids and immunosuppressive 
drugs. In our case, neither the increase of the initial 
systemic doses, nor the replacement of azathioprine by 
  cyclophosphamide, had any effect on the ocular signs of 
the disease. Even topical steroids (drops) and lubricants 
were used, but with no symptomatic effect, probably due to 
persistent erosion of the lid margins, affecting the quality 
of the tear film and further causing severe dryness of the 
eye. A considerable improvement was seen following 
2 subconjunctival injections of TA 20 mg with an interval of 
2 weeks, probably due to “normalization” of the lid margin 
anatomy, which improved ocular surface dryness. The 
improvement of the clinical condition led to the tapering of 
the systemic treatment. The subconjunctival TA injections 
provided sustained release of steroids at the side of greatest 
need, ie, the palpebral conjunctiva, with no systemic adverse 
effects. This was of particular importance in our patient who 
started to present signs of Cushing’s syndrome from the 
long-term use of systemic steroids.
To the best of our knowledge, this is the first reported 
case of subconjunctival injections of TA for the treatment of 
ocular manifestations of PV . Daouds et al7 reported 11 cases 
of ocular manifestations of PV treated mainly with systemic 
steroids, and in 1 case they used TA. The authors concluded 
that the disease could recur (mean follow up 48.9 months), Clinical Ophthalmology 2010:4
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but that finally all patients eventually recovered fully without 
sequelae. They also found TA a possible modality in unre-
sponsive cases.
In our case, TA proved more helpful. Although no 
long case series are available, TA could be regarded as an 
effective alternative for patients with serious ophthalmic 
  manifestations of PV unresponsive to systemic therapy or 
those with serious adverse effects to systemic treatment.
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